Payment overview · 2025
General Payments
$1,992.71
45 reported records · 13 companies
Healthcare provider profile · identity verified
Ronald Litman
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARION, OH · NPI 1578059630
Verified facts
What the public records show
CMS Open Payments records show Ronald Litman received $1,992.71 in general payments during 2025 across 45 reported records.
Ascensia Diabetes Care Us Inc. accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Ozempic, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $1,297.90 | 65.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.95 | 10.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.01 | 4.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.28 | 3.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $58.34 | 2.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.02 | 2.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.77 | 2.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.49 | 2.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.98 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.45 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.06 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.72 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,290.00 | 3 |
| Food and Beverage | $702.71 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.01 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.01 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.22 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $67.06 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.28 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $58.34 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $47.02 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.09 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 238 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 190 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 31 |
| Furosemide | Furosemide | 174 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 60 |
| Potassium Chloride | Potassium Chloride | 166 | 39 |
| Tramadol Hcl | Tramadol Hcl | 142 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 29 |
| Lorazepam | Lorazepam | 110 | 28 |
| Lisinopril | Lisinopril | 109 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 22 |
| Trazodone Hcl | Trazodone Hcl | 95 | 21 |
| Omeprazole | Omeprazole | 94 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 27 |
| Eliquis | Apixaban | 85 | 18 |
| Pregabalin | Pregabalin | 82 | 18 |
| Clonazepam | Clonazepam | 75 | 14 |
| Famotidine | Famotidine | 74 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Metformin Hcl | Metformin Hcl | 70 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | 22 |
| Sertraline Hcl | Sertraline Hcl | 57 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 24 |
| Methylprednisolone | Methylprednisolone | 53 | 41 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | 15 |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Prednisone | Prednisone | 49 | 28 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 14 |
| Allopurinol | Allopurinol | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 13 |
| Lactulose | Lactulose | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 15 |
| Losartan Potassium | Losartan Potassium | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 16 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Briviact | Brivaracetam | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Lacosamide | Lacosamide | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 16 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Azithromycin | Azithromycin | 30 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 16 |
| Meloxicam | Meloxicam | 29 | 16 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Nystatin | Nystatin | 27 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Cephalexin | Cephalexin | 24 | 22 |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 11 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Xifaxan | Rifaximin | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Levocarnitine | Levocarnitine | 18 | suppressed |
| Diazepam | Diazepam | 17 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Rufinamide | Rufinamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,992.71 · 45 records | Ascensia Diabetes Care Us Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, Korlym, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error